PARP1 inhibitor NU-1025 treatment prevented or delayed BCR-ABL1 mutation acquisition in CML-T1 and KCL-22 cells after the exposure to imatinib (Supplementary Results; Supplementary Figure S9). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.